59 results about "Diabetes type ii" patented technology

The invention relates to medical composition containing metformin and Vildagliptin and a preparation method thereof. The medical composition is formed by taking metformin chloride and Vildagliptin as medical active components and blending with pharmaceutically acceptable auxiliary materials; the invention adopts the metformin chloride and Vildagliptin as materials and adds auxiliary materials with some special kinds and proportions to prepare and develop diversified oral preparations such as tablets, capsules, granules, dispersible tablets, chewable tablets, buccal tablets, effervescent tablets, effervescent granules according to the technical method of the invention. The medical composition of the invention can be used for treating diabetes type II that can not be properly cured by alimentary control and sports and also for diabetes type II that can not be controlled by simply using metformin chloride or Vildagliptin.

This invention is directed to methods of treating patients with metabolic syndrome, prediabetes and / or Type II diabetes mellitus by administering docosahexaenoic acid (DHA) alone or in combination with diabetes-related medications.

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and / or long term regulation of energy balance; short-, medium- and / or long term regulation (stimulation and / or inhibition) of food intake; adipogenesis, adiposity and / or obesity; body weight gain and / or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and / or long term regulation of energy balance; short-, medium- and / or long term regulation (stimulation and / or inhibition) of food intake; adipogenesis, adiposity and / or obesity; body weight gain and / or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

The invention discloses a guava leaf extract with a function of reducing blood sugar as well as a preparation method and application thereof. The guava leaf extract with the function of reducing blood sugar is characterized by comprising 20-99% of total triterpenoid acid. The preparation method of the guava leaf extract comprises the following steps of: heating and reflowing or percolating and extracting guava leaves with ethanol or methanol; decompressing and concentrating to obtain extractum; adding water to the extractum and stirring the extractum; centrifuging; taking out sediments to obtain the guava leaf extract with the function of reducing blood sugar. The guava leaf extract can be used for preparing a medicament and a health care product for preventing and treating diabetes type II and has the advantages of clear effective part components, less toxicity, strong pharmacological effects, favorable pharmaceutical prospect, simple preparation process and easiness for large scale production.

The invention relates to the field of medicine and nutrition, more specifically to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatique, kidney disorders, metabolic syndrome or diabetes type II. The invention provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising Bifidobacterium bifidum W23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement.

This invention provides a process for extracting a pharmaceutically active fraction from the foliage (leaves and stems) and / or roots of Rauvolfia vomitoria and the fruit of Citrus aurantium. In one aspect, the process requires extracting from a boiled tea of Rauvolfia vomitoria foliage and / or roots and Citrus aurantium fruit an active fraction made by filtering the boiled tea and concentrating the supernatant. In one embodiment, the fraction is concentrated by freeze drying the supernatant. The fraction is useful to treat a disorder associated with abnormally elevated glucose levels in a subject by administering to the subject a therapeutically effective amount of the extract or a pharmaceutical composition containing the extract. Such conditions include, but are not limited to the diabetes Type II, abnormal steraroyl-CoA desaturase activity, hyperphagia, abnormal lipid mobilization, abnormal fatty acid profile from the eye of the subject, ulcers and a glucosuria.

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and / or long term regulation of energy balance, short-, medium-, and / or long term regulation (stimulation and / or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and / or obesity, body weight gain and / or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

This invention disclose novel uses of omega-3 rich phospholipids for treating diabetes type II, metabolic syndrome, sustained ventricular tachycardia and inflammatory disease. In addition to improving fertility in asthenozoospermic males. The invention also discloses the use of omega-3 rich phospholipids in healthy subject for improving physical endurances, reducing delayed onset muscle soreness as well as preventing obesity.

The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type II. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising Bifidobacterium bifidum W23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement.

The present invention discloses a health-care food for preventing or curing diabetes type II and its preparation method. It is made up by using ( by weight portion) 25-80 portions of ginseng, 21-82 portions of pueraria root, 19-72 portions of coptis root, 12-43 portions of Chinese yam, 9-15 portions of rehmannia root, 7-52 portions of fetid cassia seed, 5-46 portions of propolis and 5-15 portions of ganoderma polysaccharide through a certain preparation method. Said invention also provides the concrete steps of its preparation method.

The present invention is related to substituted methylene amide derivatives of formula (I) and use thereof for the treatment and / or prevention of metabolic disorders mediated by insulin resistance or pyperglycemia, comprising diabetes type I and / or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of substituted methylene amide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs. Also the present invention relates to a method of treating diabetes type II, obesity and to regulate the appetite of mammals. The present invention is furthermore related to novel substituted methylene amide derivatives and method of preparation thereof. Formula (I).

The present invention relates to compounds of Formula (I): wherein R1, A, Y, n and m are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of orexin-1 receptor-related disorders and orexin-2 receptor-related disorders. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders.

A method of treating early diabetic neuropathy includes administering a composition comprising an aqueous extract of olives is disclosed. A method of treating patients with Cfiber neuropathy includes administering a composition comprising an aqueous extract of olives. A method of treating patients with large fiber and C-fiber neuropathy includes administering a composition comprising an aqueous extract of olives. Preferably the aqueous extract of olives contains a weight ratio of hydroxytyrosol to oleuropein of between about 1:1 and about 400:1. More preferably, the weight ratio is between about 3:1 and about 200:1. Most preferably, the weight ratio is between about 5:1 and about 50:1. Alternately, an extract from grape leaves can be used to treat patients with large fiber and Cfiber neuropathy.

The invention relates to pharmaceutical applications of poly-cationic resin and is based on treatment on metabolic diseases due to intestinal flora disorder by orally taking the poly-cationic resin, wherein the metabolic diseases include but not limit to: 1) non-alcoholic fatty liver, nonalcoholic steatohepatitis, hepatic fibrosis caused by intestinal bacterial toxin; 2) diabetes type II; 3) central obesity metabolic syndromes; 4) endotoxemia; etc.

The present invention provides a diabetes type II gene susceptivity and pre-warning detection kit, which is characterized in that seven nucleic acid (DNA and RNA) molecule markers are combined, wherein the seven nucleic acid (DNA and RNA) molecule markers comprise APM1 (+45), CDKAL1 (rs10946398), TCF7L2 (rs7903146) , CDKN2A / 2B (rs10811661), KCNQ1 (rs2237892), VDR (FokI) and SLC30A8 (rs13266634). The kit comprises: specific amplification primer pairs and DNA sequencing primer pairs of the gene polymorphism loci, PCR reaction liquids, PCR product enzymolysis liquids and DNA sequencing reaction liquids. According to the present invention, detection is performed by using the kit, gene information is processed and analyzed, diabetes type II susceptivity of a healthy subject is evaluated, and guiding significance is provided for personalized treatment and health care of diabetes type II people.

The invention discloses a traditional Chinese medicine composition for treating diabetes type II and hyperlipoidemia. The traditional Chinese medicine composition is prepared from the following material medicines in portion by weight: 10 to 30 portions of astragalus root, 10 to 30 portions of gold theragran, 5 to 20 portions of coptis root, 10 to 20 portions of radix puerariae, 10 to 20 portions of tuckahoe, 6 to 20 portions of heterophylly falsestarwort root, 15 to 40 portions of yam, 10 to 20 portions of radix rehmanniae, 10 to 30 portions of rhizoma alismatis, 5 to 20 portions of dogwood, 10 to 30 portions of folium mori, and 5 to 20 portions of radix paeoniae rubra. The traditional Chinese medicine composition has the advantages that: all components are traditional Chinese medicines which are wide in source and relatively low in price; the traditional Chinese medicine composition can be prepared into tablets, soft capsules, hard capsules, oral liquid, pills or particles and conveniently taken; and the traditional Chinese medicine composition has simple preparation process, needs less equipment and is easy in operation.

The invention relates to a tetrahydropalmatine derivative and application thereof, a compound as shown in a formula (VI) and a preparation method thereof, and an application of the compound in medicine. Specifically, the invention relates to a derivative of the compound as shown in the general formula (VI) and a preparation method thereof, and an application of the derivative as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, diabetes type II, hyperglycemia, adiposis, or insulin resistance and metabolic syndrome. The compound disclosed by the invention also can reduce total cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides, and increases the expression of a liver LDL receptor and inhibits the expression of proprotein convertase subtilisin / kexin type 9 (PCSK9).

The invention discloses a functional sheet for adjuvant treatment on diabetes type II and a production method thereof. The functional sheet is prepared from ginkgo leaf extract, mulberry leaf extract, sea buckthorn extract, grape seed extract, black fungus polysaccharide, armillaria mellea polysaccharide, ganoderan, agaricus blazei murill polysaccharide, grifolan, starch, microcrystalline cellulose, dextrin and magnesium stearate. The production method comprises material selection, extract powder preparation, domestic fungus extract product preparation, weighing and mixing, granulation, tabletting and packaging. The functional sheet is rich in anthocyanidin, flavonoids and polysaccharide of edible fungi. The ingredients are combined, mainly act on lung, spleen and kidney channels, have effects of tonifying Qi and Yin, invigorating spleen and kidney, and engendering liquid and moistening dryness and can realize purposes of assistantly reducing blood glucose and improving patient living quality.

The invention discloses a method for preparing alogliptin, a medicine for treating type II diabetes. The method comprises: 1) in the presence of copper acetate and triethylamine, 6-chloro-3-methyluracil and 2-cyano Benzyl bromide is carried out contact reaction in acetonitrile, and after reaction finishes, reaction solution is poured into water, filters, washes with water, dries to obtain 6-chloro-1-(2-isocyanobenzyl)-3-methylpyrimidine-2, 4-(1H,3H)-dione; 2) 6-chloro-1-(2-isocyanobenzyl)-3-methylpyrimidine-2,4-(1H,3H)-dione, (R )‑3‑tert-butyloxycarbonylaminopiperidine and potassium carbonate are mixed in DMF. After the reaction, add water, then extract with dichloromethane and concentrate to obtain (R)‑tert-butyl‑1‑(3‑ (2‑isocyanobenzyl)‑1‑methyl‑2,6‑dioxo‑1,2,3,6‑tetrahydropyrimidin‑4‑yl)piperidin‑3‑ylcarbamate; 3 ) dissolving the formate ester obtained in step 2) in ethanol and reacting with benzoic acid at 65-70°C, then cooling to -5-5°C for crystallization, filtering and drying to obtain alogliptin. The invention has simple steps, high yield and faster reaction.

Short peptides and derivatives or analogs thereof for the treatment or prevention of IAAP related disorders, in particular amyloid deposits associated with Type I or Type II diabetes are herein described. These peptides and / or their derivatives have been designed to inhibit the formation of amylin fibrils which are implicated in the pathogenesis of diabetes Type II as well as to dissolve the fibrillar deposits already formed

The present invention uses kelp extract as main raw material, and adopts the processes of drying, pulverizing, adding nutrient organic chromium or some auxiliary materials according to a certain proportion, using gamma-ray radiation sterilization to make them into the invented health-care food which can be made into powder preparation, oral liquor, paste preparation, table and capsule preparation for curing diabetes type II and preventing its complication.

The invention relates to a pharmaceutical composition for treating diabetes type II. The pharmaceutical composition contains an effective dose of compound and a pharmaceutically acceptable carrier, wherein the structure of the compound is as shown in the specification. The compound provided by the invention has an obvious effect on diabetes type II and can be developed into a new pharmaceutical composition which is effective clinically.

The technical problem to be solved by the present invention is to prolong the half-life of an Exendin-4 polypeptide and to improve the stability and the safety of the existing Exendin-4 polypeptide-containing fusion protein. The scheme for solving the technical problem is to provide a new fusion protein containing the Exendin-4 polypeptide, wherein the structure of the fusion protein sequentially comprises Exendin-4, a connecting peptide, Exendin-4, a connecting peptide and an IgG4Fc mutant from the nitrogen terminal. According to the present invention, the provided fusion protein containing the Exendin-4 has characteristics of good stability, long half-life and low toxic-side effect; and the fusion protein of the invention can be used for treatment of diabetes type I and diabetes type II, and has high clinical application value.

The invention belongs to the field of medicine chemistry and relates to a 2-benzyloxyphenyloxazolopyridine compound represented as the formula (I), and a medicinal application thereof, wherein the R,X, Y and Z are coincided with details in specification. The compound can inhibit activity of sphingomyelin synthase and can be used for preparing a sphingomyelin synthase small-molecular inhibitor. The invention provides the compound represented as the formula (I) or a medicine composition employing the compound (I) as an active component, and the application of the medicine composition for preparing a medicine for preventing / treating diseases caused by abnormal increasing of sphingomyelin level, wherein the diseases include following metabolic syndromes: atherosclerosis, fatty liver, obesity,diabetes type II and the like.

Provided herein are methods of inhibiting agouti or agouti-related protein (AGRP) in a cell or in an individual in need thereof, comprising administering to the cell or the individual an effective amount of an agent that induces corin expression, activity or a combination thereof in the cell or individual. The invention also provides a method of treating obesity in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual. Further provided is a method of treating diabetes type II in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual.

A compound of formula (I) as defined hereinis useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and / or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

The present invention relates to a method of treating diabetes type II by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.

The invention discloses a crystal form of dapagliflozin and preparation method thereof. The dapagliflozin is stirred and dissolved with 1,2-propylene glycol in an organic solvent; then a low-polar solvent is added, and cooling crystallization is carried out at certain temperature; the mixture then is filtered to obtain a solid; the solid is subjected to pressure-reduced vacuum drying to prepare acrystal form compound of dapagliflozin, which has high purity and has obvious structural features of the crystal. The crystal form compound of dapagliflozin has good thermal stability and allows large-scale production. The crystal form compound and a composition thereof are mainly used for treatment on diabetes type II.

The present invention relates to a method of treating diabetes Type II by delivery of butyric acid, bile acid, long-chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.